Clinical trials
Lung clinical trials
Below are recruiting lung clinical trials, each written for real people, not researchers. We’re tracking 2,828 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06440954RecruitingPhase 2
Pemetrexed injected into spinal fluid for lung cancer that spread to brain lining
This study tests a treatment called intrathecal pemetrexed, which is chemotherapy given directly into the fluid around your brain and spine. It's for people with a specific type of lung cancer that has spread to the lining of the brain or spinal cord after targeted therapy stopped working.
Changsha, HunanAges 18 years+ - NCT07845929Recruiting
AI help for clearer low-dose CT images
This study tests an artificial intelligence model that helps create clearer images from a lower-dose CT scan, which could mean less radiation exposure during your procedure. It aims to improve image quality while keeping radiation doses as low as possible.
Hefei, AnhuiAges 18 years+ - NCT07848243RecruitingPhase 2
A new imaging test to find returning cancer
This trial tests a new imaging agent that helps find cancer cells that have come back. It is given as an injection and then a scan is done to see if it helps doctors locate the cancer.
BeijingAges 18 years+ - NCT07845942Recruiting
Donor stem cell transplant for stubborn systemic juvenile arthritis
This study tests a bone marrow transplant (using donor cells) to treat severe systemic juvenile idiopathic arthritis (sJIA) that has not responded to other treatments. The goal is to reset the immune system to stop the disease and its complications, like lung problems or recurrent macrophage activation syndrome.
Cincinnati, OhioAges Up to 35 years - NCT06445881RecruitingPhase 2
Herbal medicine for lung cancer before and after surgery
This trial is testing whether adding a traditional Chinese herbal formula (Modified Si Jun Zi Tang) to standard treatment before and after surgery can help people with early-stage non-small cell lung cancer. It aims to see if the herbs improve outcomes and reduce side effects.
Hangzhou, ZhejiangAges 18–75 - NCT04214587Recruiting
Study of removed lung valves after treatment
This study looks at lung tissue taken out after a treatment that places a one-way lung valve to help breathing. They want to learn how the valve affects the airway and lung over time.
GroningenAges Any age - NCT06371482RecruitingPhase 2
Durvalumab plus chemoradiation for limited-stage small cell lung cancer
This trial tests adding the immunotherapy drug durvalumab to standard chemotherapy and radiation for limited-stage small cell lung cancer. The goal is to see if this combination helps control the cancer better than standard treatment alone.
Shijiazhuang, HebeiAges 18–75 - NCT07841249Recruiting
Recovery of heart and lung fitness after lung surgery
This study compares how well patients recover their heart and lung fitness after two types of lung surgery: removing a whole lobe versus removing a smaller part of the lung. It may help doctors understand which surgery leads to better recovery.
Wuhan, HubeiAges 18 years+ - NCT07837739Recruiting
EGFR-targeted pill after surgery for early lung cancer
This trial tests whether taking an EGFR-targeted pill after lung cancer surgery can lower the chance of the cancer coming back. It is for people with early-stage non-small cell lung cancer that has a specific EGFR mutation.
Wuhan, HubeiAges 18–75 - NCT03198546RecruitingPhase 1
CAR T therapy for advanced liver cancer with GPC3
This Phase 1 study tests a personalized immune-cell treatment (CAR T cells) for advanced liver cancer that has the GPC3 protein. It aims to see whether these engineered cells can find and kill cancer cells safely and help shrink the cancer.
Guangzhou, GuangdongAges 18–75 - NCT07830342RecruitingPhase 1
Study of tumor-infiltrating lymphocyte therapy for advanced non-small cell lung cancer
This trial tests a new cell therapy that uses your own immune cells (TILs) to fight lung cancer. If you have advanced non-small cell lung cancer and standard treatments haven't worked, this treatment might help your immune system attack the cancer more effectively.
ShanghaiAges 18–75 - NCT05532696RecruitingPhase 1/Phase 2
Testing ABT-101 for advanced solid tumors and HER2-mutant lung cancer
This study tests ABT-101, a new experimental treatment, in people with advanced solid tumors. A second part specifically looks at people with non-small cell lung cancer (NSCLC) that has HER2 mutations, to see how well the treatment works and how safe it is.
TaichungAges 18 years+ - NCT03769129Recruiting
Pembrolizumab plus lung ablation for advanced lung cancer
This trial tests whether combining pembrolizumab (an immune treatment) with a lung ablation procedure can be safer and more effective for advanced non-small cell lung cancer after standard first treatment fails or the cancer comes back. It may help shrink tumors and improve control of the disease.
Guangzhou, GuangdongAges 18 years+ - NCT07833085Recruiting
Imaging test for solid tumors using a special tracer
This study tests a new imaging method that uses a special tracer to find solid tumors in the body. It may help doctors see tumors more clearly and guide treatment.
Wuhan, HubeiAges 18 years+ - NCT04842812RecruitingPhase 1
Personalized immune cell therapy for advanced solid tumors
This Phase 1 study tests engineered immune cells (TILs/CAR-TILs) made from your tumor to treat advanced solid cancers that have not responded to standard treatments. It may help your immune system better recognize and attack the cancer, but it is mainly focused on safety and early results.
GuangzhouAges 18–85 - NCT03192501Recruiting
Using prior scans to guide cancer treatment choices
This trial tests whether using existing “PACS” scan images to guide individualized cancer treatment (compared with standard care) can improve outcomes for people with advanced or metastatic cancer. It may help doctors make more precise treatment decisions using your past imaging.
Guangzhou, GuangdongAges 18–70 - NCT03198052RecruitingPhase 1
CAR-T cell therapy for cancers with specific protein targets
This Phase 1 study tests CAR-T cells that are engineered to recognize several cancer “markers” (specific proteins) found on some advanced cancers. It may help by directing the patient’s own immune cells to attack cancer, but eligibility depends on matching the required protein markers.
Guangzhou, GuangdongAges 18–75 - NCT03755739RecruitingPhase 2/Phase 3
Checkpoint cancer drug given into or near tumors
This trial studies whether giving immunotherapy “checkpoint inhibitor” medicine directly into the tumor area (and/or the artery feeding it), along with a chemotherapy-style drug, can work better for advanced solid tumors. It aims to boost the immune system’s ability to attack cancer while still being safe for people with measurable tumors.
Guanzhou, GuangdongAges 18 years+ - NCT05187338RecruitingPhase 1/Phase 2
Study drugs that target immune checkpoints for solid tumors
This early-phase study tests a combination of three immune “checkpoint” medicines in people with advanced solid cancers. It aims to see how well they work and what side effects occur, including when given through a specific liver-focused treatment in eligible patients.
Guangzhou, GuangdongAges 18–70 - NCT05060796RecruitingEarly Phase 1
CAR-T treatment for advanced lung cancer with EGFR and CXCL13 signs
This early-phase study tests a custom CAR-T cell therapy made to target EGFR in people with advanced non-small cell lung cancer. You may be eligible if your tumor has specific lab markers (EGFR and CXCL13) and if your overall heart, liver, kidney, and blood counts can safely support treatment.
GuangzhouAges 18–75 - NCT04952272RecruitingPhase 1
Shots into the tumor to boost the immune system
This Phase 1 study tests an injection given directly into an advanced solid tumor to help the immune system better recognize and attack cancer. It may help people with advanced solid tumors, but the goal at this early stage is mainly to check safety and how the treatment works.
Guangzhou, GuangdongAges 18–80 - NCT06472388RecruitingPhase 2
Testing two doses of everolimus for neuroendocrine tumors
This trial compares two daily doses (5 mg vs 10 mg) of everolimus, a targeted therapy, to see which works better and is safer for people with advanced neuroendocrine tumors (NETs). You may qualify if your cancer has grown despite previous treatment and you are in relatively good health.
São Paulo, São PauloAges 16 years+ - NCT06196294RecruitingPhase 1
Engineered immune cells for cancers with GPC3 or mesothelin
This trial tests a new type of immune cell therapy made from your own cells (gamma-delta T cells) that are engineered to find and attack cancers that have GPC3 or mesothelin proteins. It may be an option for people with advanced cancer who have not had gene therapy before and are in generally good health.
Guangzhou, GuangdongAges 18–75 - NCT03233087Recruiting
Study to predict outcomes in aortic dissection
This study collects medical information and blood-test timing data to learn how to diagnose aortic dissection sooner and predict outcomes. It may help doctors better plan care for people with suspected or confirmed aortic dissection.
Beijing, Beijing MunicipalityAges 18–80
Hear when a new Lung trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for lung?
- Yes. Clin2 currently lists 2,828 recruiting lung studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a lung trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a lung trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.